$RNA News
Last published 2w ago
- 2w agoRNAAtrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 SyndromePR Newswire-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants ---- Initial proof of concept data expected in second half of 2027 --SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc.
- 3w agoRNAAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement
- 3w agoRNAYakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingPR NewswireYakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty
- 1mo agoRNAAtrium Therapeutics Announces $50 Million Private PlacementPR NewswireSAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics
- 1mo agoRNAAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026...
- 2mo agoRNAAtrium Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the...
- 2mo agoRNAAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026...
- 3mo agoRNAAtrium Therapeutics Reports Second Quarter 2026 Financial ResultsPR Newswire-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --SAN DIEGO, Aug. 13,
- 3mo agoRNABMYAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationPR NewswireSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA
- 3mo agoRNAAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026...
- 4mo agoRNAAtrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 SyndromePR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced ...
- 4mo agoRNAAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026...
- 6mo agoRNAAtrium Therapeutics Reports First Quarter 2026 Financial ResultsPR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision...
- 6mo agoRNABMYAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationPR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart,...
- 6mo agoRNAAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026...
- 8mo agoRNAAtrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic CardiomyopathiesPR NewswireAtrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics...
- 8mo agoRNAAvidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferencePR NewswireAvidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called...
- 8mo agoRNAAvidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersPR NewswireAvidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called...
- 8mo agoRNAThe New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 9mo agoRNAAvidity Biosciences Announces Expected Record Date for Spin-OffPR NewswireAvidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called...
- 9mo agoRNASNOASonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product DevelopmentACCESS NewswireBOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid
- 11mo agoRNAAvidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Reports Third Quarter 2025 Financial Results and Recent HighlightsPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoNVSRNAAALYUM+23Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 1y agoRNAAvidity Biosciences Enters into Agreement to be Acquired by Novartis AGPR NewswireAvidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called...
- 1y agoRNANovartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipelineGlobeNewswireAd hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the Novartis xRNA strategy by
- 1y agoRNAAvidity Biosciences to Participate in Upcoming Investor ConferencePR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle SocietyPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces Pricing of Upsized Public Offering of Common StockPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)Earnings Call Transcripts
- 1y agoRNAAvidity Biosciences Announces Proposed Public Offering of Common StockPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoRNAAvidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoRNAAvidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoRNAAvidity Biosciences to Participate in Upcoming Investor ConferencesPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Reports Second Quarter 2025 Financial Results and Recent HighlightsPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory SubmissionPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 SkippingPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research CongressPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD ParticipantsPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHDPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Reports First Quarter 2025 Financial Results and Recent HighlightsPR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences to Participate in Upcoming Investor ConferencePR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1PR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
- 1y agoRNAAvidity Biosciences to Participate in Upcoming Investor ConferencePR NewswireAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...